Loading...
•
Dec 31, 2025
ARS Pharmaceuticals Q4 2025 Earnings Report
ARS Pharmaceuticals Q4 2025 Earnings Report
Key Takeaways
ARS Pharmaceuticals reported Q4 2025 revenue of $28.1 million, driven by the U.S. commercial launch of neffy. While the company is seeing strong adoption with over 22,500 prescribing HCPs, it recorded a net loss of $41.3 million for the quarter due to significant investments in direct-to-consumer marketing and sales force expansion.
neffy generated $20.3 million in U.S. net product revenue during the fourth quarter.
More than 22,500 healthcare providers have prescribed neffy to date, with a 50% repeat prescriber rate.
The company maintains a strong liquidity position with $245.0 million in cash and investments to fund operations through cash-flow break-even.
Global expansion is accelerating with recent approvals in China and Australia, and a positive CHMP opinion in Europe for the 1 mg dose.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
ARS Pharma expects to accelerate market share in 2026 through prescription renewals, expanded sales force, and continued DTC investment, aiming for cash-flow break-even.
Positive Outlook
- Anticipated start of prescription renewals in 2026 as initial product reaches expiration.
- Expansion of sales force from 106 to 150 representatives starting in Q2 2026.
- Expected regulatory approval and launch of neffy in Canada in 2026.
- Interim Phase 2b data for chronic spontaneous urticaria expected in 2H 2026.
- Cash position expected to fund operations through cash-flow break-even.
Challenges Ahead
- SG&A expenses expected to remain high to support continued neffy promotion.
- Ongoing need to secure unrestricted access with remaining major payors.
- Risk that DTC campaigns may not realize expected return on investment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...